This article is more than 5 years old. Information may no longer be current.

Angle-supported phakic IOL may offer strong visual, refractive outcomes

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Data from U.S. and Canadian trials suggested positive long-term outcomes for an angle-supported phakic lens used to correct moderate to high myopia, according to a specialist here.

Jeffrey D. Horn

In a presentation at the American Society of Cataract and Refractive Surgery meeting, Jeffrey D. Horn, MD, reported encouraging results for patients who underwent first-eye implantation of the AcrySof Cachet (Alcon) phakic lens.

“Five years after implantation of the AcrySof Cachet phakic lens, we were able to demonstrate good outcomes, including good visual acuity, stable postoperative refraction [and] accurate predictability of refraction,”  Dr. Horn said.

The prospective, single-arm phase 1/2 U.S. clinical trial included 56 of 60 enrolled patients at 5-year follow-up. Mean logMAR uncorrected visual acuity was 0.06 ± 0.2, and mean corrected visual acuity was –0.1 ± 0.09.

Approximately 64% of patients had 20/20 or better uncorrected vision, and roughly 93% had 20/40 or better. About 73% of patients had 20/16 or better corrected vision, and 100% had 20/30 or better.

The average rate of observed loss was no different than it would be for individuals without implantation, despite suggestions that endothelial cell loss is unpredictable with the AcrySof Cachet, Dr. Horn said.

Thaddeus T. Demong

Additionally, Thaddeus T. Demong, MD, reported long-term results from a prospective, single-arm study conducted at five centers in Canada, including outcomes for 73 patients with second-eye implantation.

“Our 4-year, second-eye implantation of the phakic IOL clinical outcomes demonstrated stable and predictable clinical outcomes with excellent visual acuity,” Dr. Demong said.

The two studies will continue through completion of 5-year follow-up.

• Disclosures: Dr. Horn is a consultant for and receives lecture fees from Alcon. Dr. Demong receives research support from Alcon, which sponsored the study he presented.